Chiara Brignola

Dr. Chiara Brignola

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Molecular Pharmaceutics
Verified
Journal Article
Open access
PCPietro Carotenuto
Pietro Carotenuto
APAnnalisa Pecoraro
Annalisa Pecoraro
CBChiara Brignola
Chiara Brignola
ABAnna Barbato
Anna Barbato
BFBrunella Franco
Brunella Franco
ARAnnapina Russo
Annapina Russo

29 January 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Francesco MerlinoFrancesco Merlino
Francesco Merlino
APAnnalisa Pecoraro
Annalisa Pecoraro
GLGiuseppe Longobardi
Giuseppe Longobardi
GDGreta Donati
Greta Donati
FLFrancesco Saverio Di Leva
Francesco Saverio Di Leva
VPValeria La Pietra
Valeria La Pietra

22 June 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
CBChiara Brignola
Chiara Brignola
APANNALISA PECORARO
ANNALISA PECORARO
CDCamilla Danisi
Camilla Danisi
NINunzia Iaccarino
Nunzia Iaccarino
APAnna Di Porzio
Anna Di Porzio
ARAnnapina Russo
Annapina Russo
Despite advancements in therapeutic strategies, the development of drug resistance and metastasis remains a serious concern for the efficacy of chemotherapy against colorectal cancer (CRC). We have previously demonstrated that low expression of ribosomal protein uL3 positively correlates with chemoresistance in CRC patients. Here, we demonstrated that the loss of uL3 increased the metastatic capacity of CRC cells in chick embryos. Metabolomic analysis revealed large perturbations in amino acid and glutathione metabolism in resistant uL3-silenced CRC cells, indicating that uL3 silencing dramatically triggered redox metabolic reprogramming. RNA-Seq data revealed a notable dysregulation of 108 genes related to ferroptosis in CRC patients. Solute Carrier Family 7 Member 11 (SLC7A11) is one of the most dysregulated genes; its mRNA stability is negatively regulated by uL3, and its expression is inversely correlated with uL3 levels. Inhibition of SLC7A11 with erastin impaired resistant uL3-silenced CRC cell survival by inducing ferroptosis. Of interest, the combined treatment erastin plus uL3 enhanced the chemotherapeutic sensitivity of uL3-silenced CRC cells to erastin. The antimetastatic potential of the combined strategy was evaluated in chick embryos. Overall, our study sheds light on uL3-mediated chemoresistance and provides evidence of a novel therapeutic approach, erastin plus uL3, to induce ferroptosis, establishing individualized therapy by examining p53, uL3 and SLC7A11 profiles in tumors.

14 May 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
CBChiara Brignola
Chiara Brignola
MCMyrhiam Cassese
Myrhiam Cassese
SMStefano Marrone
Stefano Marrone
TETeresa Esposito
Teresa Esposito
Vincenza BarresiVincenza Barresi
Vincenza Barresi
Fabio CattaneoFabio Cattaneo
Fabio Cattaneo
Cancer progression is closely linked to the enhanced uptake of extracellular amino acids, mediated by specific transporters that support biosynthesis, metabolic activity, and energy production through the tricarboxylic acid cycle. By increasing the expression of these transporters, tumor cells secure a continuous amino acid supply that sustains the proliferation, metabolic balance, and activation of major signaling pathways. While most studies have emphasized post-translational control of amino acid transporters, such as phosphorylation, ubiquitination, glycosylation, and palmitoylation, emerging evidence highlights regulatory crosstalk between these transporters and other membrane proteins, including G protein-coupled receptors and receptor tyrosine kinases. This review summarizes the current literature on the receptor-mediated mechanisms governing amino acid uptake and explores how interactions among families of membrane proteins contribute to the regulation of transporter activity.